BIOMAT Database Logo BIOMAT Database Logo

Efficacy of purified Vi polysaccharide typhoid vaccine. 2002

Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Suwon 441-744, Korea.

This experiment was conducted to assess the efficacy of typhoid vaccine newly produced by purifying Vi antigen of Salmonella typhi. With Karber method, LD50 of challenging organism (S. typhi ty2) was determined as 6.31 CFU/mouse, and then the organism was used for the study. With Probits method, ED50 of the vaccine was determined as 0.016 microg / 0.5 ml / mouse. The ELISA titer (0.5097+/-0.0606) was 4 times in the group treated with high dose (0.25 microg/0.5ml) as in control (0.1113+/-0.0110). Six major protein bands of 66, 55, 35, 33, 18, and 9 kd were detected in Western blot analysis with serum of a vaccine treated mouse, whereas only one weak band of about 35 kd was detected with serum of a control mouse. We concluded that typhoid vaccine produced by purifying Vi antigen of S. typhi very effectively prevent S. typhi infection in mice.

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D012485 Salmonella typhi A serotype of SALMONELLA ENTERICA which is the etiologic agent of TYPHOID FEVER. Salmonella enterica serovar Typhi,Salmonella typhosa
D014435 Typhoid Fever An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA. Enteric Fever,Typhus, Abdominal,Salmonella typhi Infection,Typhoid,Abdominal Typhus,Enteric Fevers,Fever, Enteric,Fever, Typhoid,Fevers, Enteric,Fevers, Typhoid,Infection, Salmonella typhi,Infections, Salmonella typhi,Salmonella typhi Infections,Typhoid Fevers,Typhoids

Related Publications

Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
January 2001, Bulletin of the World Health Organization,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
November 1987, Lancet (London, England),
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
December 2017, Vaccine,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
A new typhoid vaccine composed of the Vi capsular polysaccharide.
November 1995, Archives of internal medicine,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Experience with Vi typhoid capsular polysaccharide vaccine in the U.K.
July 1992, The Journal of infection,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever.
August 2020, The American journal of tropical medicine and hygiene,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
June 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
May 2017, Journal of pharmaceutical and biomedical analysis,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
Efficacy of Vi polysaccharide vaccine against Salmonella typhi.
March 1999, Vaccine,
Jong-Hwan Park, and Jung-Joo Hong, and Eun-Sil Choi, and Jin-Won Lee, and Jae-Hak Park
A recently developed typhoid Vi polysaccharide vaccine: rationale and clinical profile.
January 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!